US pharma giant buys Germany's Celesio in $8-bn deal

US pharmaceutical distributor McKesson on Thursday announced the purchase of German rival Celesio in a deal valued at more than $8 billion.

The combined company "will be one of the largest pharmaceutical wholesalers and providers of logistics and services in the worldwide," the German firm said in a statement.

The total transaction, including McKesson's takeover of Celesio's outstanding debt is valued at approximately $8.3 billion (6.3 billion euros, the statement added.

Both firms will keep their own separate brands.

The combined firm is expected to have annual revenue of more than $150 billion, employing some 81,500 people in 20 countries worldwide.

Earlier in the month, shares in McKesson rose sharply after the Wall Street Journal reported news of the buy-out.

add to favorites email to friend print save as pdf

Related Stories

Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

US chemists Walgreens spends $6.7 bn on 45% of Boots

Jun 19, 2012

US-based Walgreens said on Tuesday was spending $6.7 billion (£4.3 billion, 5.3 billion euros) to take a 45-percent stake in European rival Alliance Boots to create the world's largest retail pharmacy chain.

German software giant SAP unveils solid Q2 profits

Jul 12, 2012

Shares in German software giant SAP soared on Thursday as it announced what it hailed as its "best-ever second quarter performance", beating analysts' expectations for operating profits.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments